Menu Menu


/ News
Sunday, 21st April 2024 | 4,343 veterinary jobs online | 118 people actively seeking work | 5,484 practices registered

Veterinary Industry News

Send us your news

Dechra Launches New Single-dose Solution For BRD – Cyclofin

3 months ago

15th January, 2024 08h55


Dechra has launched Cyclofin, a fast-acting, injectable single-dose solution for acute bovine respiratory disease (BRD) caused by oxytetracycline sensitive Mannheimia (Pasteurella) haemolytica and Pasteurella multocida where an anti-inflammatory and anti-pyretic effect is required.

Cyclofin has proven efficacy in treating BRD and is a convenient, single-dose injectable combining two actives: flunixin-meglumine 200 mg/ml (eq. to 33.2 mg/ml flunixin meglumine) is a potent and trusted anti-inflammatory, while oxytetracycline 300 mg/ml (eq. to 323.5 mg/ml oxytetracycline trihydrate) is a first choice anti-infective (class D).  Cylofin acts within 24-36 hours and has sustained anti-bacterial activity for five to six days following a single intramuscular injection.

Administration is deep intramuscular injection in cattle and Cyclofin has a 35-day withdrawal period and a memorable dose rate of 1 ml per 10 kg body weight.   It is both convenient to use on farm and is good value for farm vets.

Alana McGlade MRCVS, national sales manager at Dechra, comments: “BRD is one of the most prevalent and costly diseases on farm and early administration of an effective and fast-acting NSAID/antibiotic combination treatment, such as Cyclofin, can help relieve discomfort and stress, alleviate pain and improve demeanour and food intake.”

Cyclofin is available in 100ml vials. For further information on Cyclofin, visit or contact your local Dechra key account manager.

More from Dechra

You might be interested in...